Previous 10 | Next 10 |
biolinerx (NASDAQ: BLRX ): FY GAAP EPS of -$0.17 beats by $2.14 . Cash and cash equivalents of $5.3M. Press Release More news on: BioLineRx Ltd., Earnings news and commentary, Healthcare stocks news, ,
TEL AVIV, Israel , March 12, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the year ended December 31, 2019 and provides a corporate update. Highlights and ...
TEL AVIV, Israel , March 6, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited financial results for the year ended December 31, 2019 on Thursday, March 1...
TEL AVIV, Israel , Feb. 27, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a pate...
BioLineRx (NASDAQ: BLRX ) has completed patient recruitment in the triple combination arm of its Phase 2a COMBAT/KEYNOTE-202 study. More news on: BioLineRx Ltd., Healthcare stocks news, Read more ...
TEL AVIV , Israel , Jan. 22, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today the completion of patient recruitment in the triple combination arm of its ongoing Phase 2a COMBAT/KEYNOTE-202 s...
Introduction A recent debate on Stocktwits between two posters (let’s call them “Moon Guy” and “Funny Guy”) inspired me to write this article and reflect upon how to play BLRX in 2020 given that my small starter position I initiated back in 2019 is down...
RTI Surgical Holdings (NASDAQ: RTIX ) +105% on sale of OEM business . More news on: RTI Surgical Holdings, Inc., TransEnterix, Inc., XBiotech Inc., Stocks on the move, , Read more ...
TEL AVIV, Israel , Jan. 14, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced that the European Commission (EC) has granted Orphan Drug Designation to its lead oncology candidate, Motixaforti...
TEL AVIV, Israel , Jan. 8, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that management will provide a corporate update at the 2020 Biotech Showcase in San Francisco, California . 202...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...